What happened
Green Lifescience updated its previously filed separate results for FY2025: revenue of US$27.2M (+62.3% year on year), operating profit of US$138K (−45.8% year on year) and net income of US$74.2K (−92.9% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$27.2M |
|---|---|
| Revenue vs a year earlier | +62.3% |
| Operating profit | US$138K |
| Net income | US$74.2K |
| Period | FY2025 (separate) |
| Filed | 2026-03-18, [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260318901234 → open original filing |
Versions of this filing
- 2026-01-26Original
- 2026-03-18Amendment 1 (this page)
Source: DART. Information only, not investment advice.